Oral Wegovy (Semaglutide Pill) Approved by the FDA in December 2025, this daily pill offers the same GLP-1 weight loss benefits as its injectable counterpart
Opened Vial Duration: Once opened and accessed via needle puncture, the vial remains viable only if aseptic technique is maintained and storage conditions are met
In 2021, semaglutides weight-loss brand Wegovy (weekly injectable) was approved for obesity, followed by tirzepatide (Mounjaro) for diabetes (2022) and Zepbound (tirzepatide for obesity) in late 2023
After our comprehensive investigation, Eden receives a 7.7/10 rating
Related Reading Mounjaro Weight Loss By Week Mounjaro For Weight Loss 2 Weight Loss Mounjaro Weight Loss Injections Mounjaro Pricing and availability current as of July 2026
Clinic Reputation: Highly reputed clinics will have experienced dermatologists following global standards and protocols, can charge more